Bioventus Inc. (NASDAQ:BVS) Q3 2025 Earnings Call Transcript
Operator: Good day, and welcome to the Bioventus Inc. Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
Bioventus Inc. (BVS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Juniper Investment Company Alexis Michas And John Bartholdson | 6,939,357 | $51,628,816 | 17.75% | |
| 2. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 6,047,403 | $44,992,678 | +5% | 1.49% |
| 3. | Royce & Associates Chuck Royce | 1,251,282 | $9,309,538 | -1% | 0.09% |
| 4. | Renaissance Technologies Jim Simons | 615,100 | $4,576,344 | -25% | 0.01% |
| 5. | Eversept Partners Kamran Moghtaderi | 471,257 | $3,506,152 | +9% | 0.18% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.55 | 25,500 | $217,966.35 | 6,939,357 | 2024-08-19 | Filing | |
| $8.55 | 80,000 | $683,736.00 | 6,913,857 | 2024-08-16 | Filing | |
| $4.14 | 26,595 | $110,071.39 | 26,595 | 2023-08-18 | Filing | |
| $4.14 | 13,290 | $55,004.65 | 138,290 | 2023-08-18 | Filing | |
| $4.79 | 14,985 | $71,752.68 | 6,833,857 | 2023-08-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.57 | 10,000 | $75,658.00 | 116,610 | 2025-12-04 | Filing | |
| $7.42 | 17,701 | $131,254.69 | 56,997 | 2025-11-07 | Filing | |
| $7.57 | 3,875 | $29,333.75 | 141,088 | 2025-04-11 | Filing | |
| $7.57 | 2,958 | $22,392.06 | 131,416 | 2025-04-11 | Filing | |
| $7.57 | 1,283 | $9,712.31 | 55,557 | 2025-04-11 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,021,324 | $96,878,651 | 30.44% | |
| 2. | 3,124,184 | $23,243,930 | 0% | |
| 3. | 2,984,927 | $22,207,857 | 0% | |
| 4. | 1,120,238 | $8,337,051 | 0% | |
| 5. | 891,024 | $6,629,219 | 0% |
News See All
Craig-Hallum Reiterates a Buy Rating on Bioventus (BVS), Sets a $15 PT
Bioventus Inc. (NASDAQ:BVS) is one of the best medical device stocks to buy according to analysts. On August 7, Craig-Hallum analyst Chase Knickerbocker reiterated a Buy rating on Bioventus Inc.
12 Best Medical Device Stocks to Buy According to Analysts
On July 7, CNBC’s Chery Kang and Elaine Yu talked about China’s imposition of reciprocal tariffs on the import of medical devices from the European Union.
Bioventus Inc. (NASDAQ:BVS) Q2 2025 Earnings Call Transcript
Operator: Thank you for standing by. My name is Carly, and I will be your conference operator today. At this time, I would like to welcome everyone to the Bioventus Inc.
10 Undervalued Medical Device Stocks to Buy Now
According to a report by Mordor Intelligence, the medical device industry is valued at $681.57 billion as of 2025.
Bioventus Inc. (NASDAQ:BVS) Q1 2025 Earnings Call Transcript
Operator: Good day, and welcome to the Bioventus First Quarter 2025 Conference Call. [Operator Instructions] Please note this event is being recorded.
Bioventus Inc. (NASDAQ:BVS) Q4 2024 Earnings Call Transcript
Operator: Good morning and welcome to the Bioventus Fourth Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.
Bioventus Inc. (NASDAQ:BVS) Q3 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Bioventus Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
Bioventus Inc. (NASDAQ:BVS) Q2 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Bioventus Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions].
Bioventus Inc. (NASDAQ:BVS) Q1 2024 Earnings Call Transcript
Bioventus Inc. beats earnings expectations. Reported EPS is $0.07, expectations were $-0.05. Bioventus Inc.
Hedge Fund Resource Center Billionaire Hedge Funds
